Renowned financial commentator Jim Cramer has labeled Johnson & Johnson (JNJ) a 'terrific entry point' in a recent market appearance, boosting sentiment around the healthcare giant. The endorsement comes as JNJ trades near $162.40, offering a forward dividend yield of 3.1%.
- JNJ trading at $162.40 with a 3.1% forward dividend yield
- Year-to-date stock decline: 4.3%, outperforming S&P 500’s 6.1% drop
- Fiscal 2025 adjusted EPS: $7.82, with pharma contributing 62% of revenue
- 28% spike in trading volume following Cramer’s commentary
- 19% increase in retail investor interest in JNJ positions over 24 hours
- JNJ among top 10 most-searched financial symbols in the past day
Jim Cramer, the widely followed host of CNBC’s 'Mad Money,' has publicly recommended Johnson & Johnson (JNJ) as an attractive buying opportunity, calling the current price a 'terrific entry point.' The statement, made during a live segment on January 8, 2026, highlights JNJ’s resilience amid broader market fluctuations and its strong fundamentals in a sector under scrutiny for regulatory and litigation risks. JNJ’s current share price of approximately $162.40 reflects a modest 4.3% decline year-to-date, outperforming the S&P 500’s 6.1% drop over the same period. The stock’s 3.1% forward dividend yield remains well above the S&P 500’s average of 1.6%, reinforcing its appeal to income-oriented investors. The company reported fiscal 2025 adjusted EPS of $7.82, with pharmaceuticals contributing 62% of total revenue, underscoring its diversified growth engine. Market impact has been immediate, with JNJ’s trading volume rising 28% above its 50-day average within the first hour of the commentary. Retail investor interest, tracked via option flow and ETF inflows, shows a 19% increase in JNJ-related positions over the past 24 hours. The stock is also among the top 10 most-searched names on major financial platforms, reflecting heightened attention. While Cramer’s remarks are not a formal buy recommendation, they carry significant influence, particularly among retail traders. The endorsement may encourage risk-tolerant investors to initiate positions or add to existing holdings, potentially driving short-term momentum. However, long-term performance will remain tied to JNJ’s ability to manage ongoing legal liabilities and continue innovation in biopharmaceuticals.